Clinical TrialsNotable's lead program, volasertib, has shown clinical activity across liquid and solid tumors in phase I/II/III studies.
Diagnostic AdvancementAt AACR, the company presented a companion diagnostic to predict volasertib responders, enhancing the trial's potential success.
Research PresentationThe company recently presented two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024).